

Methylation profiling report

Supplier information

Sample identifier: **sampleName1573992189**
Sentrix ID: **203057710094_R08C01**
Material type: **KRYO DNA**
Gender: **NA**
Supplier diagnosis: **-**

Automatic prediction		
Array type:	EPIC	
Material type:	KRYO DNA	✓
Gender:	male	!
Legend: ✓ OK ! Supplier information or prediction not available ✗ Warning, mismatch of prediction and supplier information		

Brain tumor methylation classifier results (v11b4)

Methylation classes (MCs with score >= 0.3)	Calibrated score	Interpretation
methylation class family Glioblastoma, IDH wildtype	0.99	match ✓
MC family members with score >= 0.1		
methylation class glioblastoma, IDH wildtype, subclass RTK I	0.96	match ●


Legend: ✓ Match (score >= 0.9) ✗ No match (score < 0.9): possibly still relevant for low tumor content and low DNA quality cases. ● Match to MC family member (score >= 0.5)

Class descriptions

Methylation class family Glioblastoma, IDH wildtype: The methylation class family "Glioblastoma, IDH wildtype" comprises the methylation classes glioblastoma, IDH wildtype, subtype RTK I to III, glioblastoma, IDH wildtype, subtype mesenchymal, glioblastoma, IDH wildtype, subtype MYCN and glioblastoma, IDH wildtype, subtype midline.


Methylation class glioblastoma, IDH wildtype, subclass RTK I: The methylation class "glioblastoma, IDH wildtype, subclass RTK I" is comprised of tumors with a histological diagnosis of glioblastoma, IDH wildtype. The tumors are located in the cerebral hemispheres. Median age is 64 years (range 29 to 84). Recurrent chromosomal alterations are gain of chromosome 7 with or without EGFR amplification (>80%), loss of 9p21 (CDKN2A/B; >50%) and chromosome 10 loss (>70%). Amplifications of the PDGFRA oncogene are enriched in this class (present in 20-30% of cases). Expression profiles often resemble the 'Proneural' subgroup according to the TCGA classification.

Copy number variation profile



Depiction of chromosome 1 to 22 (and X/Y if automatic prediction was successful). Gains/amplifications represent positive, losses negative deviations from the baseline. 29 brain tumor relevant gene regions are highlighted for easier assessment.
(see Hovestadt & Zapatka, <http://www.bioconductor.org/packages/devel/bioc/html/conumee.html>)

MGMT promotor methylation (MGMT-STP27)



(see Bady et al, J Mol Diagn 2016; 18(3):350-61)

Disclaimer

Classification using methylation profiling is a research tool under development, it is not verified and has not been clinically validated. Implementation of the results in a clinical setting is in the sole responsibility of the treating physician. Intended for non-commercial use only.

Run information

Report: idat_reportBrain_v11b4_sample Version 2.0
Task version:

Task	Version
idat_qc	2.0
idat_predictBrain	2.1
idat_rs_gender	2.0
idat_predictMGMT	2.0
idat_cnvp	3.0
idat_reportBrain_v11b4	2.0